Clinical trial
Autoimmunity Contributes to the Severe Progression of COVID-19
NCT04967781 is registered in ClinicalTrials.gov with Zhongnan Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Autoimmunity Contributes to the Severe Progression of COVID-19
- Lead sponsor
- Zhongnan Hospital
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 10, 2020
- Completion date
- May 27, 2021
- Enrollment
- 162 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
coronavirus disease 2019